TherapeuticsMD Inc(TXMD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 23 at 4:00 PM ET (Korea 10/24 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.02 | Insider Own | 8.45% | Shs Outstand | 11.6M | Perf Week | -5.26% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 10.6M | Perf Month | -15.49% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | - | Inst Own | 31.68% | Short Float | 0.22% | Perf Quarter | -13.04% |
| Income | -0.00B | P/S | 6.37 | EPS this Y | - | Inst Trans | -0.76% | Short Ratio | 0.97 | Perf Half Y | -17.81% |
| Sales | 0.00B | P/B | 0.77 | EPS next 5Y | - | ROA | -0.78% | Short Interest | 0.02M | Perf YTD | 10.43% |
| Book/sh | 2.34 | P/C | 2.27 | EPS past 3/5Y | 83.18% 72.84% | ROE | -1.08% | 52W High | -38.98% ($2.95) | Perf Year | 37.4% |
| Cash/sh | 0.79 | P/FCF | 6.68 | Sales past 3/5Y | -64.91% -45.84% | ROIC | -0.69% | 52W Low | 62.16% ($1.11) | Perf 3Y | -17.43% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 52.88% | Gross Margin | 49.36% | Volatility(W/M) | 5.77% 3.62% | Perf 5Y | -95.31% |
| Dividend TTM | - | EV/Sales | 5.26 | Sales Y/Y TTM | 27.78% | Oper. Margin | -117.8% | ATR (14) | 0.08 | Perf 10Y | -99.42% |
| Dividend Ex-Date | - | Quick Ratio | 2.76 | EPS Q/Q | -72.06% | Profit Margin | -6.64% | RSI (14) | 28.62 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.76 | Sales Q/Q | -8.72% | SMA20 | -8.65% ($1.97) | Beta | 0.67 | Target Price | $5 |
| Payout | - | Debt/Eq | 0.2 | Earnings | 2026/8/11 | SMA50 | -13.28% ($2.08) | Rel Volume | 0.64 | Prev Close | $1.85 |
| Employees | 1 | LT Debt/Eq | 0.17 | EPS/Sales Surpr. | - | SMA200 | -15.25% ($2.12) | Avg Volume(3M) | 0.02M | Price | $1.8 |
| IPO | 2002/1/3 | Option/Short | Yes/Yes | Trades | 116 | Volume | 15,715 | Change | -2.7% |
👩⚕️ This is a U.S. royalty-based women's health company that licenses out the commercialization rights for its self-developed hormone therapy products—IMVEXXY and BIJUVA—and the contraceptive ring ANNOVERA to Mayne Pharma and other partners in exchange for royalties. With no in-house sales or R&D operations, its business model centers entirely on licensing and royalty income.
Over the past 1 year, roughly in the middle
39% below its 1-year high.
Traded less than usual. That is 64% of its average volume.
TXMD has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $637. Peers typically go for $196. Compared with its own 2-year average, it is 2333% pricier now.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -95.3%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 31.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #69 of 83 in the industry
Based on market cap of $21M.
FAQ
What kind of company is TXMD?
TXMD belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of TXMD?
The market cap of TXMD is approximately $21M, ranking 5,213 within its sector.
What is the 52-week high and low for TXMD?
TXMD has recorded a 52-week high of $2.95 and a low of $1.11.
